Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
St Bartholomew's Hospital · Queen Mary University of London · +25 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
273
total citations
- FWCI
- 38.98
- Percentile
- 100%
- References
- 21
Citations per year
Authors
233- TPThomas PowlesCorresponding
St Bartholomew's Hospital, Queen Mary University of London, Royal Free London NHS Foundation Trust, University College London
- PTPiotr Tomczak
Poznan University of Medical Sciences
- SHSe Hoon Park
Samsung Medical Center, Sungkyunkwan University
- BVBalaji Venugopal
Beatson West of Scotland Cancer Centre, University of Glasgow
- TFThomas Ferguson
Fiona Stanley Hospital
Topics & keywords
Topics
Keywords
- Medicine
- Renal cell carcinoma
- Placebo
- Clinical endpoint
- Interim analysis
- Population
- Nephrectomy
- Pembrolizumab
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.